進行がん患者におけるPF-07994525を評価するためのオープンラベル研究
進行性悪性腫瘍患者におけるPF-07994525を評価するための非盲検第1相試験
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Colorado Blood Cancer Institute
-
Denver、Colorado、アメリカ、80218
- 募集
- Presbyterian/St. Luke's Medical Center
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- 募集
- Smilow Cancer Hospital Phase 1 Unit
-
New Haven、Connecticut、アメリカ、06510
- 募集
- Yale-New Haven Hospital-Yale Cancer Center
-
New Haven、Connecticut、アメリカ、06510
- 募集
- Smilow Cancer Hospital - Yale New Haven Health
-
New Haven、Connecticut、アメリカ、06511
- 募集
- Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
-
North Haven、Connecticut、アメリカ、06473
- 募集
- Smilow Cancer Hospital - North Haven
-
-
Florida
-
Coral Gables、Florida、アメリカ、33146
- 募集
- Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
-
Coral Springs、Florida、アメリカ、33065
- 募集
- Sylvester Comprehensive Cancer Center - Coral Springs
-
Deerfield Beach、Florida、アメリカ、33442
- 募集
- University of Miami Hospital and Clinics - Deerfield Beach
-
Doral、Florida、アメリカ、33166
- 募集
- Sylvester Comprehensive Cancer Center- Doral
-
Hollywood、Florida、アメリカ、33021
- 募集
- Sylvester Comprehensive Cancer Center - Hollywood
-
Miami、Florida、アメリカ、33136
- 募集
- Sylvester Comprehensive Cancer Center
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami Hospital and Clinics
-
Miami、Florida、アメリカ、33176
- 募集
- Sylvester Comprehensive Cancer Center- Kendall
-
North Miami、Florida、アメリカ、33181
- 募集
- Sylvester Comprehensive Cancer Center - Sole Mia
-
Plantation、Florida、アメリカ、33324
- 募集
- Sylvester Comprehensive Cancer Center - Plantation
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- 募集
- Emory University Hospital Midtown
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Winship Cancer Institute, Emory University
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- The James Cancer Hospital and Solove Research Institute
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University Hospitals
-
Columbus、Ohio、アメリカ、43210
- 募集
- The James Outpatient Care West Campus
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Sarah Cannon Research Institute - Pharmacy
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Tristar BMT
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology Partners
-
Nashville、Tennessee、アメリカ、37203
- 募集
- TriStar Centennial Medical center
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- 募集
- Arthur J.E. Child Comprehensive Cancer Centre
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8V 5C2
- まだ募集していません
- Juravinski Cancer Centre
-
Toronto、Ontario、カナダ、M5G2M9
- 募集
- University Health Network- Princess Margaret Cancer Centre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at the time of informed consent.
- Prior diagnosis of MM as defined according to IMWG criteria (Rajkumar et al. 2014)
Measurable disease based on IMWG criteria as defined by at least 1 of the following:
-
Serum M-protein >0.5 g/dL by serum protein electrophoresis (SPEP)
-
Urinary M-protein excretion >200 mg/24 hours by urine protein electrophoresis (UPEP)
-
Serum immunoglobulin Free Light Chain (FLC) ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65)
- Participants must be refractory to, or intolerant to, all established therapies known to provide clinical benefit in multiple myeloma that are an appropriate therapeutic option, in the judgement of the investigator. A minimum of 3 prior lines of therapy are required.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Active plasma cell leukemia, Smoldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome.
- Autologous stem cell transplant within 12 weeks prior to enrollment or active Graft-versus-host disease (GVHD).
- Active or suspected cerebral/meningeal disease related to the underlying malignancy.
- Any active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), known HIV or AIDS related illness, unless deemed not clinically significant by the investigator (eg, onychomycosis).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1
Monotherapy Dose Expansion |
Oral administration Oral administration |
|
実験的:Part 2
Monotherapy Dose Escalation |
Oral administration |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Type, incidence and severity of participants with adverse events (AEs)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, severity (graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), timing, seriousness, and relatedness of adverse events (AEs) |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Type, incidence and severity of participants with laboratory abnormalities
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Type, incidence, and severity (graded by NCI CTCAE version 5.0) of laboratory abnormalities |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Number of participants with dose modifications
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Frequency of dose modifications (eg, dose delay, treatment interruptions, dose reductions, and treatment discontinuations) due to AEs |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
時間枠:Baseline to end of DLT evaluation period
|
Occurrence of DLTs as defined by the protocol |
Baseline to end of DLT evaluation period
|
|
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
RDE will be based on cumulative safety, preliminary antitumor activity and pharmacokinetics findings |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Part 2: Recommended Dose for future development
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Safety, and preliminary anti-tumor activity |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
国際骨髄腫ワーキンググループ(IMWG)の反応基準に基づき、研究者が判定した客観的奏効率(ORR)。
時間枠:ベースラインから疾患進行、死亡、または新規抗癌療法開始の最初の記録日まで(約2年間)
|
ベースラインから疾患進行、死亡、または新規抗癌療法開始の最初の記録日まで(約2年間)
|
|
|
国際骨髄腫作業部会(IMWG)の反応基準に基づき、研究者により判定された完全反応率(CRR)。
時間枠:ベースラインから疾患進行、死亡、または新規抗癌療法開始の最初の記録日まで(約2年間)
|
ベースラインから疾患進行、死亡、または新規抗癌療法開始の最初の記録日まで(約2年間)
|
|
|
IMWGによる研究者判定による反応時間(TTR)
時間枠:ベースラインから疾患進行、死亡、または新規抗がん剤治療の開始が最初に記録された日まで(約2年)
|
ベースラインから疾患進行、死亡、または新規抗がん剤治療の開始が最初に記録された日まで(約2年)
|
|
|
調査責任者により決定されたIMWG基準に基づく奏効持続期間(DOR)
時間枠:ベースラインから疾患進行の初回記録日、死亡、または新規抗癌療法開始までの期間(約2年間)
|
ベースラインから疾患進行の初回記録日、死亡、または新規抗癌療法開始までの期間(約2年間)
|
|
|
IMWGによる完全奏効期間(DOCR)を、試験責任医師が判定
時間枠:ベースラインから、疾患進行、死亡、または新たな抗癌療法開始の初回文書化日まで(約2年間)
|
ベースラインから、疾患進行、死亡、または新たな抗癌療法開始の初回文書化日まで(約2年間)
|
|
|
治験責任医師が判断したIMWGによる無増悪生存期間(PFS)
時間枠:ベースラインから疾患進行、死亡、または新規抗癌療法の開始の最初の記録日まで(約2年間)
|
ベースラインから疾患進行、死亡、または新規抗癌療法の開始の最初の記録日まで(約2年間)
|
|
|
全生存期間(OS)
時間枠:ベースラインから疾患進行の初回文書化、死亡、または新規抗癌療法開始の日付まで(約2年間)
|
ベースラインから疾患進行の初回文書化、死亡、または新規抗癌療法開始の日付まで(約2年間)
|
|
|
Single, Multiple Dose and food effect: Maximum Observed Concentration (Cmax)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Time to Maximum concentration (Tmax)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: AUC from time zero to time of last measurable concentration (AUClast)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: Terminal Elimination half-life (t1/2) as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single Dose and food effect: AUC versus time curve from time 0 extrapolated to infinity (AUCinf) as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: apparent clearance of drug (CL/F) as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Single, Multiple Dose and food effect: Apparent volume of distribution during terminal phase (Vz/F) as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: AUC at steady state over the dosing interval (AUCtau) as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Cmin as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Multiple Dose: Accumulation ratio (Rac) as data permit
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
Pharmacokinetic (PK) assessments for PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
AUC from time zero to time of last measurable concentration (AUClast)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Time to Maximum concentration (Tmax)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
|
Maximum Observed Concentration (Cmax)
時間枠:From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
PK parameters of CYP3A4 probe substrate midazolam with and without PF-07994525 |
From the first day through 30-37 days after the last study treatment, up to approximately 2 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- C6331001
- KAT2i (その他の識別子:Alias Study Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。